Teva Pharmaceutical Industries LTD Form 4 insider transactions

Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries, sold shares of Teva stock on March 4th and 5th, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Mark Sabag, Executive Vice President at Teva Pharmaceutical Industries, reports the vesting and disposal of restricted share units resulting in changes to his beneficial ownership of ordinary shares.

Executive Vice President of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports the sale of ordinary shares to cover tax obligations and pursuant to a pre-arranged trading plan.

CEO Richard Francis sold Teva Pharmaceutical Industries shares to cover tax withholding obligations related to vesting restricted share units, while also acquiring shares through the vesting of these units.

Amir Weiss, Chief Accounting Officer of Teva Pharmaceutical Industries, reports the disposal of ordinary shares following the vesting of restricted share units.

Executive Vice President of International Markets at Teva Pharmaceutical Industries, Mark Sabag, reports the vesting and subsequent disposal of 24,900 restricted share units, resulting in the acquisition of 24,900 ordinary shares and a decrease in his holdings of restricted share units.

Executive VP of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports exercising restricted share units and selling ordinary shares on March 3 and 4, 2025, under a pre-arranged trading plan.

Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries, reported the sale of ordinary shares on March 3rd and 4th, 2025, following the vesting of restricted share units.

CEO Richard Francis sold Teva Pharmaceutical Industries shares to cover tax withholding obligations related to vesting restricted share units, as part of a pre-arranged Rule 10b5-1 trading plan.

EVP and CFO of Teva Pharmaceutical Industries, Eliyahu Sharon Kalif, reports the sale of 55,750 ordinary shares and the exercise of options for 49,800 shares.

Teva Pharmaceutical's CEO, Richard Francis, sold shares to cover tax obligations related to vesting restricted share units, as disclosed in a recent SEC filing.

Executive Vice President of International Markets at Teva Pharmaceutical Industries, Mark Sabag, sold 177,626 ordinary shares at an average price of $16.2508 on February 12, 2025.

Executive VP of European Commercial at Teva Pharmaceutical Industries, Richard Daniell, reports acquisition of 183,169 restricted share units following performance criteria satisfaction.

Mark Sabag, EVP of International Markets at Teva Pharmaceutical Industries, acquired 183,169 restricted share units on January 28, 2025, following the satisfaction of performance criteria.

Eliyahu Sharon Kalif, EVP and CFO of Teva Pharmaceutical Industries, reports the acquisition of 183,169 restricted share units on January 28, 2025, convertible to ordinary shares, following the satisfaction of performance criteria.

Roberto Mignone, a director at Teva Pharmaceutical Industries, sold 286,000 ordinary shares at a weighted average price of $22.0071 on December 20, 2024.

Teva Pharmaceutical Industries director Chen Lichtenstein was granted 4,804 restricted share units on December 2, 2024, which vest on December 2, 2025.

Christine Fox, EVP at Teva Pharmaceutical Industries, sold 19,388 ordinary shares to cover tax obligations after 63,492 restricted share units vested.

Director Varda Shalev reports the acquisition and disposal of Teva Pharmaceutical Industries Ltd. ordinary shares related to vested restricted share units.

Richard Daniell, Executive VP of European Commercial at Teva Pharmaceutical Industries, sold 98,943 ordinary shares on August 12, 2024.

EVP of Business Development at Teva Pharmaceutical Industries, Angus Grant, reports the sale of shares to cover tax withholding obligations related to vesting restricted share units.

Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries Ltd, sold 45,060 ordinary shares at a weighted average price of $17.3762 on August 9, 2024.

Eric A. Hughes, Executive Vice President at Teva Pharmaceutical Industries, reports the vesting of restricted share units and subsequent sale of shares to cover tax obligations.

Executive Vice President Placid Jover reports the acquisition of 51,311 restricted share units in Teva Pharmaceutical Industries on August 1, 2024.

Director Roberto Mignone sold 519,000 ordinary shares of Teva Pharmaceutical Industries at a weighted average price of $17.03, while also correcting previous filings regarding direct ownership.

Director Tal Zvi Zaks reports a transaction involving Teva Pharmaceutical Industries' ordinary shares and restricted share units.

Roberto Mignone, a director of Teva Pharmaceutical Industries Ltd., reports the acquisition and disposal of ordinary shares and restricted share units.

Director Rosemary Crane reports the acquisition of 21,108 ordinary shares of Teva Pharmaceutical Industries through the vesting of restricted share units.

Director Ronit Satch-Fainaro reported the vesting and disposal of restricted share units resulting in the acquisition of ordinary shares of Teva Pharmaceutical Industries.

Director Perry Nisen reports the vesting and subsequent disposal of restricted share units resulting in the acquisition and disposal of ordinary shares.